PALATIN TECHNOLOGIES INC

Listed Company

PTNCIK 0000911216NYSENon-AcceleratedSmaller ReportingPharmaceutical PreparationsNew JerseyFY ends Jun 30

Period

FY 2025

Revenue

Net Income

$-17.31M

Total Assets

$3.27M

Equity

$-4.78M

Shares Out

1.77M

Op. Cash Flow

$-21.31M

Business

Palatin Technologies Inc is a biopharmaceutical company that discovers and develops receptor-specific therapeutics targeting the melanocortin receptor (MCR) system. It develops peptide and small-molecule MCR agonists and antagonists, including MC4R-focused candidates for obesity and metabolic disorders and MC1R-focused peptides for inflammatory and autoimmune and ocular indications such as dry eye and ulcerative colitis. Key business activities include research and development of clinical-stage programs, IND-enabling activities, and pursuing strategic alliances and licensing for development, manufacturing and commercialization. Products are advanced through clinical trials and regulatory pathways and are intended for commercialization via partnerships, licensees and contract manufacturers in the U.S. and international markets.

Summary from filing dated 2025-09-23

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30
Product revenue, net	0	4	5	1	−188,597
Cost of products sold	0	97,637	—	—	—
Research and development	15	22	23	21	13
Selling, general and administrative	8	12	15	17	—
Loss (Gain) on sale of Vyleesi	−3	−8	—	—	—
Gain on purchase commitment	−2	0	−1	0	—
Total operating expenses	17	27	37	38	33
Loss from operations	−17	−22	−32	−37	−33
Investment income	167,665	376,843	691,981	29,963	23,572
Foreign currency transaction (loss) gain	−50	59,753	−429,971	389,868	−212,526
Interest expense	−15,025	−17,114	−20,013	−29,682	−23,440
Offering expenses	0	−696,912	−1	—	—
Change in fair value of warrant liabilities	0	−7	—	—	—
Total other income (expense), net	152,590	−7	4	390,149	—
NET LOSS	−17	−30	−24	−36	−34
Basic and diluted net loss per common share	−32.15	−101.16	—	—	—
Weighted average number of common shares outstanding used in computing basic and diluted net loss per common share	538,348	293,951	—	—	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30
Cash and cash equivalents	3	10	8	30	60
Other receivables	29,468	0	—	—	—
Prepaid expenses and other current assets	325,695	242,272	2	2	3
Total current assets	3	10	16	35	66
Property and equipment, net	129,444	388,361	684,910	539,314	94,817
Right-of-use assets - operating leases	161,166	527,321	876,101	878,465	1
Other assets	56,916	56,916	56,916	56,916	56,916
Total assets	3	11	18	36	67
Accounts payable	7	4	4	3	640,650
Accrued expenses	881,412	4	7	7	6
Short-term operating lease liabilities	129,812	380,542	354,052	371,124	351,853
Short-term finance lease liabilities	0	46,014	106,392	100,921	0
Other current liabilities	0	944,150	4	6	4
Total current liabilities	8	10	15	16	11
Long-term operating lease liabilities	33,969	163,782	544,323	529,398	900,520
Other long-term liabilities	0	1	2	—	—
Total liabilities	8	11	20	20	18
Common stock of $0.01 par value authorized 300,000,000 shares: issued and outstanding 929,597 shares as of June 30, 2025 and 358,532 shares as of June 30, 2024	9,296	3,585	116,567	92,709	92,020
Additional paid-in capital	454	442	410	404	401
Accumulated deficit	−459	−442	−412	−388	−352
Total stockholders deficiency	−5	−111,497	−2	16	50
Total liabilities and stockholders deficiency	3	11	18	36	67

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30
Net loss	−17	−30	−28	−36	—
Depreciation and amortization	258,917	339,075	288,331	126,668	—
Decrease in right-of-use asset	366,155	348,780	371,339	—	—
Unrealized foreign currency transaction loss (gain)	50	−59,753	429,971	−389,868	—
Stock-based compensation	1	2	2	3	3
Change in fair value of liability classified warrants	0	7	5	—	—
Gain on sale of Vyleesi	−3	−8	0	—	—
Accounts receivable	0	3	1	−199,577	−2
Other receivables	−29,468	0	—	—	—
Prepaid expenses and other assets	−83,423	1	35,173	1	−2
Inventories	0	−1	−418,471	217,529	−987,237
Accounts payable	3	−201,598	1	3	−75,022
Accrued expenses	−3	−2	−364,157	1	558,281
Operating lease liabilities	−380,543	−354,051	−371,122	−351,851	−316,279
Other liabilities	141,400	−3	−2	—	—
Net cash used in operating activities	−21	−31	−29	−30	−93,638
Maturity of marketable securities	0	3	0	—	—
Proceeds from sale of Vyleesi	3	10	—	—	—
Purchases of property and equipment	0	−42,526	−433,927	−261,374	−5,722
Net cash provided by investing activities	3	12	−3	−261,374	−5,722
Payment of withholding taxes related to restricted stock units	−99,482	−56,401	−146,062	−221,311	−93,638
Proceeds from the sale of common stock and warrants, net	8	15	11	0	—
Payment of finance lease obligations	−46,014	−106,392	−100,922	−56,463	0
Proceeds from exercise of warrants	3	6	78	280,000	0
Net cash provided by financing activities	11	21	11	18,358	−23
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	−7	2	−22	−30	−23
Cash paid for interest	15,025	17,114	20,013	29,682	23,440
Conversion of liability classified warrants	—	11	—	—	—
Conversion of liability classified warrants upon warrant exercise	0	2	0	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro